Skip to main content
UniHealth

Doctor search

Siba P Raychaudhuri, MD

Rheumatology · Sacramento

NPI 1821033275

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
Not verified
Not the same as out of network.
Office
1

Offices

1 location · Regents of the Univ of CA · 1,571 clinicians in this group

Looking this up.

Hospitals listed: University of California Davis Medical Center. That is not proof they admit you there this week.

Plan participation

Not verified

We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Raychaudhuri’s office at (916) 827-7463 to ask if they take your plan before you enroll.

California Medical Board record

Licence A52869 · Current

Licensed to practise in California · since 1994 · expires 2027-12-31 · University of Calcutta Medical College.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • University of California Davis Medical CenterSacramento, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UC Davis Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 74% would definitely recommend it
    Overall rating: 4 of 5 starsWorse than the national rate — Abdominopelvic accidental puncture or laceration rate: 1.94 (1.18 to 2.71) · 3,010 cases, Jul 2022 – Jun 2024Worse than the national rate — MRSA Bacteremia: 1.564, Oct 2024 – Sep 2025Worse than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 6.7 (5.6 to 8) · 1,134 cases, Jan 2024 – Dec 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.6 (10.9 to 14.5) · 1,134 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 127.46 (95.81 to 159.1) · 281 cases, Jul 2022 – Jun 2024Better than the national rate — Pressure ulcer rate: 0.18 (0 to 0.57) · 12,625 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.677, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.713, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,436 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for University of California Davis Medical Center

Behind the star rating — Deaths: 4 better, 4 the same, 0 worse of 8 measures. Safety: 0 better, 7 the same, 1 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at University of California Davis Medical Center
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.94 (1.18 to 2.71) · 3,010 casesWorseJul 2022 – Jun 2024
MRSA BacteremiaInfections1.564WorseOct 2024 – Sep 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.7 (5.6 to 8) · 1,134 casesWorseJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12.6 (10.9 to 14.5) · 1,134 casesWorseJan 2024 – Dec 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths127.46 (95.81 to 159.1) · 281 casesBetterJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.18 (0 to 0.57) · 12,625 casesBetterJul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.677BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.713BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.8 (0.7 to 1) · 2,436 casesBetterJan 2024 – Dec 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.98 (0.78 to 1.19)No differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.2 · 82 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.2 · 165 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths11.2 · 115 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.7 · 662 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.1 · 463 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 406 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.9 · 4,328 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.22 (0.05 to 0.39) · 13,828 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.3 (0.13 to 0.46) · 14,152 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths4.29 (2.92 to 5.66) · 4,920 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.78 (0.46 to 3.09) · 2,250 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.07 (1.06 to 3.09) · 4,696 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths9.46 (5.18 to 13.75) · 2,102 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths6.35 (3.74 to 8.96) · 2,191 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths2.48 (1.19 to 3.77) · 1,169 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4.3 · 127 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.826No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.899No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.669No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits14.2 · 131 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits21.2 · 751 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-25.8 · 127 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits24.1 · 758 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits23.6 · 477 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits17.6 · 469 casesNoneJul 2023 – Jun 2025
Rate of readmission after hip/knee replacementUnplanned return visits5.7 · 140 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.9 · 65 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits18.3 · 203 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits11.8 (9.4 to 14.9) · 2,643 casesNo differentJan 2022 – Dec 2024

What patients said (2,768 patients answered, 18% of those asked)

Patient survey stars by topic at University of California Davis Medical Center
Cleanliness2
Nurse communication3
Doctor communication3
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness1
Recommend hospital4
Share of patients giving the best answer at University of California Davis Medical Center
Room was "always" clean61%
Nurses "always" communicated well76%
Doctors "always" communicated well78%
Staff "always" explained60%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand72%
Doctors "always" listened carefully76%
Doctors "always" treated them with courtesy and respect85%
Patients who gave a rating of "9" or "10" (high)68%
Staff "always" explained new medications73%
Nurses "always" explained things so they could understand71%
Nurses "always" listened carefully74%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night37%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects47%
Yes, staff "did" give patients information about possible symptoms89%

Original Medicare doctor bills

$6,115

Medicare paid this office $6,115 for 49 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)18$2,301$110
Return visit (30+ min)21$1,754$76
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's18$274$13

Who their Medicare patients are

49 Original Medicare patients in 2024. Average age 70 · Women 69% · Also on Medicaid 37% · Health risk score 1.81. Sicker patients than 9 in 10 peers; the typical rheumatology clinician is at 1.38.

Conditions among them: High blood pressure 71% · Diabetes 31% · Depression 24% · Coronary heart disease 22% · Chronic kidney disease 22%.

The office billed $40,383, Medicare allowed $8,422 and paid $6,115; for 88 services of 9 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20244988701.81$40,383$6,115
20233752691.54$24,557$3,948
20223039661.68$19,902$3,408
20211324682.09$8,903$1,941
20191835682.72$11,371$2,440
20181732682.19$10,366$2,078
20161427593.28$8,663$2,367
20151430603.79$8,189$2,390

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 1 service

Original Medicare services billed in 2023
Return visit (30+ min)17$1,240$65

Money from drug and device companies

$19,910 in 2025

Industry payments by year
2025638$14,400$19,910
202436$1,350$1,548
2023310$11,250$12,612
202222None$151
202125$6,750$6,807
202069$20,165$20,385
2019513$11,398$13,682

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
AbbvieSkyrizi$10,719
11 payments
  • Paid to speak or teach for Skyrizi · 2025-12-22 · $3,500
  • Meals for Skyrizi · 2025-12-18 · $107
  • Travel for Skyrizi · 2025-12-18 · $532
  • Meals for Skyrizi · 2025-12-02 · $34
  • Travel for Skyrizi · 2025-12-02 · $868
  • Meals for Skyrizi · 2025-10-29 · $47
  • Paid to speak or teach for Skyrizi · 2025-09-17 · $2,500
  • Meals for Skyrizi · 2025-08-28 · $109
  • Paid to speak or teach for Rinvoq · 2025-05-30 · $2,500
  • Travel for Rinvoq · 2025-05-15 · $476
  • Meals for Rinvoq · 2025-05-15 · $45
Sun Pharmaceutical IndustriesIlumya$5,211
8 payments
  • Meals for Ilumya · 2025-08-19 · $8
  • Travel for Ilumya · 2025-08-08 · $228
  • Meals for Ilumya · 2025-08-08 · $79
  • Travel for Ilumya · 2025-08-08 · $41
  • Travel for Ilumya · 2025-08-08 · $41
  • Travel for Ilumya · 2025-08-08 · $626
  • Travel for Ilumya · 2025-08-08 · $187
  • Consulting for Ilumya · 2025-08-08 · $4,000
Takeda Pharmaceuticals U.S.A.None$1,963
15 payments
  • Meals · 2025-02-08 · $25
  • Meals · 2025-02-08 · $25
  • Meals · 2025-02-08 · $50
  • Meals · 2025-02-08 · $125
  • Travel · 2025-02-08 · $91
  • Travel · 2025-02-08 · $130
  • Travel · 2025-02-08 · $606
  • Meals · 2025-02-07 · $25
  • Meals · 2025-02-07 · $50
  • Meals · 2025-02-07 · $75
  • Travel · 2025-02-07 · $210
  • Meals · 2025-02-06 · $75
  • Meals · 2025-02-06 · $125
  • Travel · 2025-02-06 · $141
  • Travel · 2025-02-06 · $210
E.R. Squibb & Sons L.L.C.None$1,900
1 payment
  • Consulting · 2025-05-30 · $1,900
UcbCimzia$93
2 payments
  • Meals for Bimzelx · 2025-10-26 · $45
  • Meals for Cimzia · 2025-05-21 · $48
Merck Sharp & DohmeNone$26
1 payment
  • Education · 2025-10-30 · $26
See all 38 published payments
Every published payment
AbbviePaid to speak or teach · 2025-12-22Skyrizi$3,500
AbbvieMeals · 2025-12-18Skyrizi$107
AbbvieTravel · 2025-12-18Skyrizi$532
AbbvieMeals · 2025-12-02Skyrizi$34
AbbvieTravel · 2025-12-02Skyrizi$868
Merck Sharp & DohmeEducation · 2025-10-30None$26
AbbvieMeals · 2025-10-29Skyrizi$47
UcbMeals · 2025-10-26Bimzelx$45
AbbviePaid to speak or teach · 2025-09-17Skyrizi$2,500
AbbvieMeals · 2025-08-28Skyrizi$109
Sun Pharmaceutical IndustriesMeals · 2025-08-19Ilumya$8
Sun Pharmaceutical IndustriesTravel · 2025-08-08Ilumya$228
Sun Pharmaceutical IndustriesMeals · 2025-08-08Ilumya$79
Sun Pharmaceutical IndustriesTravel · 2025-08-08Ilumya$41
Sun Pharmaceutical IndustriesTravel · 2025-08-08Ilumya$41
Sun Pharmaceutical IndustriesTravel · 2025-08-08Ilumya$626
Sun Pharmaceutical IndustriesTravel · 2025-08-08Ilumya$187
Sun Pharmaceutical IndustriesConsulting · 2025-08-08Ilumya$4,000
E.R. Squibb & Sons L.L.C.Consulting · 2025-05-30None$1,900
AbbviePaid to speak or teach · 2025-05-30Rinvoq$2,500
UcbMeals · 2025-05-21Cimzia$48
AbbvieTravel · 2025-05-15Rinvoq$476
AbbvieMeals · 2025-05-15Rinvoq$45
Takeda Pharmaceuticals U.S.A.Meals · 2025-02-08None$25
Takeda Pharmaceuticals U.S.A.Meals · 2025-02-08None$25
Takeda Pharmaceuticals U.S.A.Meals · 2025-02-08None$50
Takeda Pharmaceuticals U.S.A.Meals · 2025-02-08None$125
Takeda Pharmaceuticals U.S.A.Travel · 2025-02-08None$91
Takeda Pharmaceuticals U.S.A.Travel · 2025-02-08None$130
Takeda Pharmaceuticals U.S.A.Travel · 2025-02-08None$606
Takeda Pharmaceuticals U.S.A.Meals · 2025-02-07None$25
Takeda Pharmaceuticals U.S.A.Meals · 2025-02-07None$50
Takeda Pharmaceuticals U.S.A.Meals · 2025-02-07None$75
Takeda Pharmaceuticals U.S.A.Travel · 2025-02-07None$210
Takeda Pharmaceuticals U.S.A.Meals · 2025-02-06None$75
Takeda Pharmaceuticals U.S.A.Meals · 2025-02-06None$125
Takeda Pharmaceuticals U.S.A.Travel · 2025-02-06None$141
Takeda Pharmaceuticals U.S.A.Travel · 2025-02-06None$210
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $1,548

Payments by company in 2024
Eli Lilly andNone$1,350
1 payment
  • Consulting · 2024-04-11 · $1,350
UcbBimzelx$189
4 payments
  • Travel for Bimzelx · 2024-01-04 · $33
  • Travel for Bimzelx · 2024-01-04 · $36
  • Meals for Bimzelx · 2024-01-04 · $42
  • Meals for Bimzelx · 2024-01-04 · $79
Lilly USATaltz$8
1 payment
  • Meals for Taltz · 2024-04-18 · $8

2023: $12,612

Payments by company in 2023
UcbBimzelx$9,825
8 payments
  • Consulting · 2023-10-09 · $8,550
  • Meals · 2023-09-23 · $13
  • Meals · 2023-09-23 · $13
  • Meals · 2023-09-23 · $50
  • Meals · 2023-09-23 · $50
  • Travel for Bimzelx · 2023-09-22 · $49
  • Travel for Bimzelx · 2023-09-22 · $307
  • Travel for Bimzelx · 2023-09-22 · $792
Eli Lilly andNone$2,700
1 payment
  • Consulting · 2023-10-10 · $2,700
Novartis PharmaceuticalsCosentyx$88
1 payment
  • Meals for Cosentyx · 2023-11-13 · $88

2022: $151

Payments by company in 2022
Novartis PharmaceuticalsCosentyx$88
1 payment
  • Meals for Cosentyx · 2022-11-12 · $88
AmgenAvsola$63
1 payment
  • Meals for Avsola · 2022-11-11 · $63

2021: $6,807

Payments by company in 2021
AbbVieNone$4,057
4 payments
  • Travel · 2021-10-28 · $28
  • Paid to speak or teach · 2021-09-07 · $2,500
  • Meals · 2021-08-30 · $29
  • Paid to speak or teach · 2021-05-10 · $1,500
Janssen Scientific AffairsTremfya$2,750
1 payment
  • Consulting for Tremfya · 2021-04-13 · $2,750

2020: $20,385

Payments by company in 2020
Eli Lilly andNone$7,000
1 payment
  • Consulting · 2020-09-16 · $7,000
Janssen Scientific AffairsTremfya$6,325
1 payment
  • Consulting for Tremfya · 2020-05-11 · $6,325
Ucb SaNone$3,840
1 payment
  • Consulting · 2020-06-18 · $3,840
AbbVieRinvoq$3,030
4 payments
  • Paid to speak or teach · 2020-11-23 · $1,500
  • Education for Rinvoq · 2020-10-30 · $15
  • Education for Rinvoq · 2020-10-30 · $15
  • Paid to speak or teach · 2020-09-29 · $1,500
Sanofi-Aventis U.S.Kevzara$99
1 payment
  • Education for Kevzara · 2020-02-18 · $99
Genentech USAActemra$91
1 payment
  • Education for Actemra · 2020-10-22 · $91

2019: $13,682

Payments by company in 2019
Novartis PharmaceuticalsCosentyx$7,298
4 payments
  • Travel for Cosentyx · 2019-03-15 · $205
  • Travel for Cosentyx · 2019-03-15 · $194
  • Consulting for Cosentyx · 2019-03-15 · $6,798
  • Meals for Cosentyx · 2019-03-15 · $101
Janssen BiotechTremfya$6,168
6 payments
  • Consulting for Tremfya · 2019-08-27 · $4,600
  • Travel for Tremfya · 2019-08-27 · $127
  • Travel for Tremfya · 2019-08-23 · $1,343
  • Meals for Tremfya · 2019-08-23 · $15
  • Meals for Tremfya · 2019-08-23 · $34
  • Meals for Tremfya · 2019-08-23 · $50
Sanofi-Aventis U.S.Kevzara$94
1 payment
  • Meals for Kevzara · 2019-11-11 · $94
Sun Pharmaceutical IndustriesIlumya$75
1 payment
  • Meals for Ilumya · 2019-04-18 · $75
GenzymeRheumatoid Arthritis Disease$47
1 payment
  • Meals for Rheumatoid Arthritis Disease · 2019-05-23 · $47

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Novartis Pharmaceuticals Corporation · Mechanisms of Action of Il17 F in Psoriatic Arthritis · 2025Their institution$97,474
ABBVIE INC. · Regulatory Role of the Jak-1 Signaling System in Psoriatic Disease Mechanism of Action of Upadacitinib (Abt-494) on Plaque and Pannus Formation · 2024Their institution$74,238
Novartis Pharmaceuticals Corporation · Mechanisms of Action of Il17 F in Psoriatic Arthritis · 2024Their institution$62,585
Eli Lilly and Company · Taltz Psa Observational Study · 2024Their institution$56,310
ABBVIE INC. · Regulatory Role of the Jak-1 Signaling System in Psoriatic Disease: Mechanism of Action of Upadacitinib (Abt-494) on Plaque and Pannus Formation. · 2022Their institution$49,963
PFIZER INC. · Xeljanz · 2019Their institution$41,100
AbbVie, Inc. · Rinvoq · 2019Their institution$28,946
ABBVIE INC. · Regulatory Role of the Jak-1 Signaling System in Psoriatic Disease: Mechanism of Action of Upadacitinib (Abt-494) on Plaque and Pannus Formation. · 2023Their institution$28,550
SUN PHARMACEUTICAL INDUSTRIES INC. · Pet Imaging Study in the Cia Mouse Model for Therapeutic Response of Anti-Il23 Antibody · 2021Their institution$28,278
AbbVie, Inc. · 2019Their institution$27,616
AbbVie Inc. · Rinvoq · 2020Their institution$22,375
Janssen Research & Development, LLC · East Bay Institute for Research & Education Psoriasis Study · 2020Their institution$21,176
ABBVIE INC. · A Study Comparing Upadacitinib (Abt-494) To Placebo and To Adalimumab in Participants With Psoriatic Arthritis Who Have An Inadequate Response To at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (Dmard) · 2024Their institution$20,573
ABBVIE INC. · A Study Comparing Upadacitinib (Abt-494) To Placebo and To Adalimumab in Participants With Psoriatic Arthritis Who Have An Inadequate Response To at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (Dmard) · 2022Their institution$14,731
ABBVIE INC. · A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (Abt-494) To Placebo and To Adalimumab in Subjects With Active Psoriatic Arthritis Who Have A History of Inadequate Response To at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (Dmard) - Select - Psa 1 · 2021Their institution$11,162
Novartis Pharmaceuticals Corporation · Mechanisms of Action of Secukinumab in Psa Rgulatory Role on Fls and Endothelial Cell Biology and Its Relevance To Pannus Formation in Psa · 2019Their institution$8,789
ABBVIE INC. · A Study Comparing Upadacitinib (Abt-494) To Placebo and To Adalimumab in Participants With Psoriatic Arthritis Who Have An Inadequate Response To at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (Dmard) · 2023Their institution$7,548
Eli Lilly and Company · Taltz Psa Observational Study · 2025Their institution$1,000
NOVARTIS PHARMACEUTICALS CORPORATION · Research Related Publications Support · 2019This clinician$287
Amgen Inc. · Etanercept Monotherapy in Psa · 2019Their institution$28

Professional record

NPI
1821033275
Licence
CA A52869California A52869: Current · expires 2027-12-31
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207RR0500X (207RR0500X)
Mailing address
510 Ashton Ave, Palo Alto, CA, 94306
NPI first listed
2006-06-19
NPI last updated
2026-07-13

This is when the NPI record was last certified, not a medical board exam.